Chemical Properties
| form | Liquid |
| color | Colorless to light yellow |
Lenzilumab Chemical Properties,Usage,Production
Uses
Lenzilumab (KB 003) is a human monoclonal antibody targeting CSF2/GM-CSF for COVID-19, chronic myelomonocytic leukemia (CMML) and juvenile myelomonocytic leukemia (JMML) studies[1][2].in vivo
Lenzilumab (i.p., 10 mg/kg, daily, 10 days) inhibits GM-CSF without inhibiting the cellular function of CAR-T and enhances its antitumor activity in NSG mice[1].
| Animal Model: | NSG mice with CART19 cells[1] |
| Dosage: | 10 mg/kg |
| Administration: | Intraperitoneal injection; daily; 10 days |
| Result: | Neutralized GM-CSF, had antitumor activity and improved the proliferation of cytokine release syndrome (CRS) and neuroinflammation (NI). |
References
[1] Rosalie M Sterner, et al. GM-CSF inhibition reduces cytokine release syndrome and neuroinflammation but enhances CAR-T cell function in xenografts. Blood. 2019 Feb 14;133(7):697-709. DOI:10.1182/blood-2018-10-881722[2] Zelalem Temesgen, et al. GM-CSF Neutralization With Lenzilumab in Severe COVID-19 Pneumonia: A Case-Cohort Study. Mayo Clin Proc. 2020 Nov;95(11):2382-2394. DOI:10.1016/j.mayocp.2020.08.038
Lenzilumab Suppliers
Global(22)Suppliers
| Supplier | Tel | Country | ProdList | Advantage | |
|---|---|---|---|---|---|
| +1-631-485-4226 | inquiry@bocsci.com | 19934 | 58 | ||
| +1-781-999-5354; | support@targetmol.com | 38999 | 58 | ||
| 027-87008169 17762441161 | info@atagenix.com | 9997 | 58 | ||
| 18916372613 | yanzihan@shyuanye.com | 87240 | 60 | ||
| 4008200310 15002144251 | marketing@tsbiochem.com | 24951 | 58 | ||
| 13370042665 18916960931 | 3623107365@qq.com | 17234 | 58 | ||
| 6206333 13167063860 | anhua.mao@aladdin-e.com | 49544 | 58 | ||
| 18007167883 18007167883 | Service@mabnus.com | 921 | 58 | ||
| 021-10000000 13000000000 | gzj@abmole.cn | 9322 | 58 | ||
| 027-027-16602739303 16602739303 | 673003916@qq.com | 4951 | 58 |